These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21370922)

  • 1. Catalytic versus inhibitory promiscuity in cytochrome P450s: implications for evolution of new function.
    Foti RS; Honaker M; Nath A; Pearson JT; Buttrick B; Isoherranen N; Atkins WM
    Biochemistry; 2011 Apr; 50(13):2387-93. PubMed ID: 21370922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into molecular basis of cytochrome p450 inhibitory promiscuity of compounds.
    Cheng F; Yu Y; Zhou Y; Shen Z; Xiao W; Liu G; Li W; Lee PW; Tang Y
    J Chem Inf Model; 2011 Oct; 51(10):2482-95. PubMed ID: 21875141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Directed evolution of cytochrome P450 enzymes for biocatalysis: exploiting the catalytic versatility of enzymes with relaxed substrate specificity.
    Behrendorff JB; Huang W; Gillam EM
    Biochem J; 2015 Apr; 467(1):1-15. PubMed ID: 25793416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential catalytic promiscuity of the alkaline phosphatase superfamily bimetallo core reveals mechanistic features underlying enzyme evolution.
    Sunden F; AlSadhan I; Lyubimov A; Doukov T; Swan J; Herschlag D
    J Biol Chem; 2017 Dec; 292(51):20960-20974. PubMed ID: 29070681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A quantitative index of substrate promiscuity.
    Nath A; Atkins WM
    Biochemistry; 2008 Jan; 47(1):157-66. PubMed ID: 18081310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme Promiscuous Activity: How to Define it and its Evolutionary Aspects.
    De Luca V; Mandrich L
    Protein Pept Lett; 2020; 27(5):400-410. PubMed ID: 31868141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.
    Hendrychová T; Anzenbacherová E; Hudeček J; Skopalík J; Lange R; Hildebrandt P; Otyepka M; Anzenbacher P
    Biochim Biophys Acta; 2011 Jan; 1814(1):58-68. PubMed ID: 20656072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stochastic ensembles, conformationally adaptive teamwork, and enzymatic detoxification.
    Atkins WM; Qian H
    Biochemistry; 2011 May; 50(19):3866-72. PubMed ID: 21473615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes.
    Li T; Li N; Guo Q; Ji H; Zhao D; Xie S; Li X; Qiu Z; Han D; Chen X; You Q
    Eur J Drug Metab Pharmacokinet; 2011 Dec; 36(4):249-56. PubMed ID: 21713461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-Shell Amino Acid R266 Helps Determine
    Truong DP; Rousseau S; Machala BW; Huddleston JP; Zhu M; Hull KG; Romo D; Raushel FM; Sacchettini JC; Glasner ME
    Biochemistry; 2021 Dec; 60(50):3829-3840. PubMed ID: 34845903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein promiscuity: drug resistance and native functions--HIV-1 case.
    Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
    J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing higher throughput methods to assess drug-drug interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 in vitro using a single point IC(50).
    Gao F; Johnson DL; Ekins S; Janiszewski J; Kelly KG; Meyer RD; West M
    J Biomol Screen; 2002 Aug; 7(4):373-82. PubMed ID: 12230892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlling substrate specificity and product regio- and stereo-selectivities of P450 enzymes without mutagenesis.
    Polic V; Auclair K
    Bioorg Med Chem; 2014 Oct; 22(20):5547-54. PubMed ID: 25035263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
    Minoletti C; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of promiscuity among drug metabolizing enzymes and drug transporters.
    Atkins WM
    FEBS J; 2020 Apr; 287(7):1306-1322. PubMed ID: 31663687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition and induction of cytochrome P450 and the clinical implications.
    Lin JH; Lu AY
    Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catalytic promiscuity in the RNA World may have aided the evolution of prebiotic metabolism.
    Vörös D; Könnyű B; Czárán T
    PLoS Comput Biol; 2021 Jan; 17(1):e1008634. PubMed ID: 33497378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro metabolism of a novel PPAR gamma agonist, KR-62980, and its stereoisomer, KR-63198, in human liver microsomes and by recombinant cytochrome P450s.
    Kim KB; Seo KA; Yoon YJ; Bae MA; Cheon HG; Shin JG; Liu KH
    Xenobiotica; 2008 Sep; 38(9):1165-76. PubMed ID: 18609447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of human cytochrome P450s involved in the bioactivation of clozapine.
    Dragovic S; Gunness P; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
    Drug Metab Dispos; 2013 Mar; 41(3):651-8. PubMed ID: 23297297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multienzyme Kinetics and Sequential Metabolism.
    Wienkers LC; Rock BM
    Methods Mol Biol; 2021; 2342():89-112. PubMed ID: 34272692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.